Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2018

View Archived Issues

Astellas grants Cardurion license for PDE9 inhibitor with potential in heart failure

Merck & Co. initiates two phase III studies for PCV-15

FDA expands approval of Vonvendi to include perioperative management of bleeding in adults with VWD

Akcea and Ionis complete inotersen licensing transaction

Enanta Pharmaceuticals unveils new compound for HBV infection

Exosomal miRNAs linked to radioresistant lung adenocarcinoma

Theralase updates results from phase Ib study of TLD-1433 in nonmuscle invasive bladder cancer

DSMB recommends continuation of phase I/IIa study of VBI-1901 in recurrent GBM

FDA approves Tavalisse for chronic ITP

Targeting NLRP3 shows promise for NASH and fibrosis

Third endometriosis program enters phase I under Evotec and Bayer alliance

Anavex to initiate phase II trial of ANAVEX2-73 in Parkinson's disease dementia

EPL-1410 demonstrates potential as immune-oncology therapeutic in preclinical models

FDA grants orphan drug designation to KL-1333 for inherited mitochondrial respiratory chain diseases

Asahi Kasei Pharma initates phase III study of isavuconazole for deep-seated mycosis

BioAtla describes activity of anti-ROR2 antibody-drug conjugate BA-3021

GlaxoSmithKline patents novel TrpV4 antagonists

Mission Therapeutics divulges new USP30 inhibitors

Mironid identifies novel PDE4 activators

Pfizer launches Besponsa in Japan

Bayer patents novel IRAK-4 inhibitors

FDA approves Crysvita for X-linked hypophosphatemia in children and adults

New compounds for asthma presented by Sichuan Haisco Pharmaceutical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
Insilico Medicine synthesizes new Nav1.8 blockers
BioWorld Science
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.